{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:45:28Z","timestamp":1793814328239,"version":"4.6.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41584-020-00515-9","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T13:03:10Z","timestamp":1603371790000},"page":"689-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":317,"title":["Immune-mediated necrotizing myopathy: clinical features and pathogenesis"],"prefix":"10.1038","volume":"16","author":[{"given":"Yves","family":"Allenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-5797","authenticated-orcid":false,"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-307X","authenticated-orcid":false,"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"515_CR1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug, C. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann. Rheum. Dis. 74, 1551\u20131556 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"515_CR3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs, R. C. et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705\u2013713 (1995).","journal-title":"Ann. Neurol."},{"key":"515_CR4","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","volume":"83","author":"WH Reeves","year":"1986","unstructured":"Reeves, W. H., Nigam, S. K. & Blobel, G. Human autoantibodies reactive with the signal-recognition particle. Proc. Natl Acad. Sci. USA 83, 9507\u20139511 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"515_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"515_CR6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","volume":"73","author":"T Miller","year":"2002","unstructured":"Miller, T., Al-Lozi, M. T., Lopate, G. & Pestronk, A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J. Neurol. Neurosurg. Psychiatry 73, 420\u2013428 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"515_CR7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713\u2013721 (2011).","journal-title":"Arthritis Rheum."},{"key":"515_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/path.1710970204","volume":"97","author":"B Smith","year":"1969","unstructured":"Smith, B. Skeletal muscle necrosis associated with cainoma. J. Pathol. 97, 207\u2013210 (1969).","journal-title":"J. Pathol."},{"key":"515_CR9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/jnnp.33.3.398","volume":"33","author":"H Urich","year":"1970","unstructured":"Urich, H. & Wilkinson, M. Necrosis of muscle with carcinoma: myositis or myopathy? J. Neurol. Neurosurg. Psychiatry 33, 398\u2013407 (1970).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"515_CR10","doi-asserted-by":"crossref","first-page":"11781","DOI":"10.1016\/S0021-9258(17)39098-1","volume":"260","author":"R Kole","year":"1985","unstructured":"Kole, R. et al. Alu RNA-protein complexes formed in vitro react with a novel lupus autoantibody. J. Biol. Chem. 260, 11781\u201311786 (1985).","journal-title":"J. Biol. Chem."},{"key":"515_CR11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","volume":"33","author":"IN Targoff","year":"1990","unstructured":"Targoff, I. N., Johnson, A. E. & Miller, F. W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 33, 1361\u20131370 (1990).","journal-title":"Arthritis Rheum."},{"key":"515_CR12","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine, L. et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 62, 2757\u20132766 (2010).","journal-title":"Arthritis Rheum."},{"key":"515_CR13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","volume":"93","author":"Y Allenbach","year":"2014","unstructured":"Allenbach, Y. et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 93, 150\u2013157 (2014).","journal-title":"Medicine"},{"key":"515_CR14","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","volume":"16","author":"L Drouot","year":"2014","unstructured":"Drouot, L. et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res. Ther. 16, R39 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"515_CR15","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai, K. et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 75, 1528\u20131537 (2018).","journal-title":"JAMA Neurol."},{"key":"515_CR16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","volume":"79","author":"I Pinal-Fernandez","year":"2020","unstructured":"Pinal-Fernandez, I. et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann. Rheum. Dis. 79, 1234\u20131242 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach, Y., Mammen, A. L., Benveniste, O., Stenzel, W. & Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul. Disord. 28, 87\u201399 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"515_CR18","first-page":"1955","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 76, 1955\u20131964 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"515_CR19","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","volume":"90","author":"Y Allenbach","year":"2018","unstructured":"Allenbach, Y. et al. Necrosis in anti-SRP+ and anti-HMGCR+ myopathies: role of autoantibodies and complement. Neurology 90, e507\u2013e517 (2018).","journal-title":"Neurology"},{"key":"515_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/WCO.0b013e328364e9d9","volume":"26","author":"Y Allenbach","year":"2013","unstructured":"Allenbach, Y. & Benveniste, O. Acquired necrotizing myopathies. Curr. Opin. Neurol. 26, 554\u2013560 (2013).","journal-title":"Curr. Opin. Neurol."},{"key":"515_CR21","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1073\/pnas.77.12.7112","volume":"77","author":"P Walter","year":"1980","unstructured":"Walter, P. & Blobel, G. Purification of a membrane-associated protein complex required for protein translocation across the endoplasmic reticulum. Proc. Natl Acad. Sci. USA 77, 7112\u20137116 (1980).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"515_CR22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/299691a0","volume":"299","author":"P Walter","year":"1982","unstructured":"Walter, P. & Blobel, G. Signal recognition particle contains a 7S RNA essential for protein translocation across the endoplasmic reticulum. Nature 299, 691\u2013698 (1982).","journal-title":"Nature"},{"key":"515_CR23","doi-asserted-by":"crossref","first-page":"485051","DOI":"10.1155\/2010\/485051","volume":"2010","author":"C Zwieb","year":"2010","unstructured":"Zwieb, C. & Bhuiyan, S. Archaea signal recognition particle shows the way. Archaea 2010, 485051 (2010).","journal-title":"Archaea"},{"key":"515_CR24","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar1895","volume":"8","author":"K R\u00f6misch","year":"2006","unstructured":"R\u00f6misch, K., Miller, F. W., Dobberstein, B. & High, S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res. Ther. 8, R39 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"515_CR25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","volume":"63","author":"O Benveniste","year":"2011","unstructured":"Benveniste, O. et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 63, 1961\u20131971 (2011).","journal-title":"Arthritis Rheum."},{"key":"515_CR26","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1172\/JCI92876","volume":"127","author":"R Carapito","year":"2017","unstructured":"Carapito, R. et al. Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features. J. Clin. Invest. 127, 4090\u20134103 (2017).","journal-title":"J. Clin. Invest."},{"key":"515_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","volume":"343","author":"JL Goldstein","year":"1990","unstructured":"Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425\u2013430 (1990).","journal-title":"Nature"},{"key":"515_CR28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0021-9258(18)89764-2","volume":"260","author":"L Liscum","year":"1985","unstructured":"Liscum, L. et al. Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum. J. Biol. Chem. 260, 522\u2013530 (1985).","journal-title":"J. Biol. Chem."},{"key":"515_CR29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/ATVBAHA.111.240754","volume":"32","author":"S Nagashima","year":"2012","unstructured":"Nagashima, S. et al. Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death. Arterioscler. Thromb. Vasc. Biol. 32, 1824\u20131831 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"515_CR30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","volume":"466","author":"Y Osaki","year":"2015","unstructured":"Osaki, Y. et al. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy. Biochem. Biophys. Res. Commun. 466, 536\u2013540 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"515_CR31","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference, B. A. et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med. 375, 2144\u20132153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"515_CR32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker, B. A. et al. Effect of statins on skeletal muscle function. Circulation 127, 96\u2013103 (2013).","journal-title":"Circulation"},{"key":"515_CR33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen, A. L. et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 64, 269\u2013272 (2012).","journal-title":"Arthritis Care Res."},{"key":"515_CR34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-016-8867-x","volume":"65","author":"O Shovman","year":"2017","unstructured":"Shovman, O. et al. Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure. Immunol. Res. 65, 276\u2013281 (2017).","journal-title":"Immunol. Res."},{"key":"515_CR35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer, A. et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54, 50\u201363 (2015).","journal-title":"Rheumatology"},{"key":"515_CR36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","volume":"9","author":"J R\u00f6nnelid","year":"2009","unstructured":"R\u00f6nnelid, J. et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun. Rev. 9, 58\u201361 (2009).","journal-title":"Autoimmun. Rev."},{"key":"515_CR37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","volume":"87","author":"Y Watanabe","year":"2016","unstructured":"Watanabe, Y. et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J. Neurol. Neurosurg. Psychiatry 87, 1038\u20131044 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"515_CR38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez, I. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 69, 263\u2013270 (2017).","journal-title":"Arthritis Care Res."},{"key":"515_CR39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi, T. et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 69, 1088\u20131094 (2017).","journal-title":"Arthritis Care Res."},{"key":"515_CR40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","volume":"29","author":"M Ueki","year":"2019","unstructured":"Ueki, M. et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod. Rheumatol. 29, 351\u2013356 (2019).","journal-title":"Mod. Rheumatol."},{"key":"515_CR41","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki, S. et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J. Rare Dis. 10, 61 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"515_CR42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","volume":"65","author":"GJD Hengstman","year":"2006","unstructured":"Hengstman, G. J. D. et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann. Rheum. Dis. 65, 1635\u20131638 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR43","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell, S. et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann. Rheum. Dis. 78, 996\u20131002 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR44","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0000000000003160","volume":"87","author":"Y Ohnuki","year":"2016","unstructured":"Ohnuki, Y. et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology 87, 1954\u20131955 (2016).","journal-title":"Neurology"},{"key":"515_CR45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","volume":"49","author":"EH Kang","year":"2019","unstructured":"Kang, E. H. et al. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Semin. Arthritis Rheum. 49, 283\u2013287 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"515_CR46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","volume":"56","author":"W-C Liang","year":"2017","unstructured":"Liang, W.-C. et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology 56, 287\u2013293 (2017).","journal-title":"Rheumatology"},{"key":"515_CR47","volume":"10","author":"Y Ge","year":"2015","unstructured":"Ge, Y., Lu, X., Peng, Q., Shu, X. & Wang, G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 10, e0141616 (2015).","journal-title":"PLoS One"},{"key":"515_CR48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","volume":"52","author":"V Limaye","year":"2015","unstructured":"Limaye, V. et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52, 196\u2013203 (2015).","journal-title":"Muscle Nerve"},{"key":"515_CR49","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen, A. L. et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 64, 1233\u20131237 (2012).","journal-title":"Arthritis Care Res."},{"key":"515_CR50","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach, Y. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain J. Neurol. 139, 2131\u20132135 (2016).","journal-title":"Brain J. Neurol."},{"key":"515_CR51","volume":"3","author":"M Kadoya","year":"2016","unstructured":"Kadoya, M. et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol. Neuroimmunol. Neuroinflamm. 3, e290 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"515_CR52","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou, E. et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology 56, 787\u2013794 (2017).","journal-title":"Rheumatology"},{"key":"515_CR53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.50.3.764","volume":"50","author":"MI Levin","year":"1998","unstructured":"Levin, M. I., Mozaffar, T., Al-Lozi, M. T. & Pestronk, A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50, 764\u2013767 (1998).","journal-title":"Neurology"},{"key":"515_CR54","first-page":"557","volume":"9","author":"HJ Vu","year":"2011","unstructured":"Vu, H. J., Pham, D., Makary, R., Nguyen, T. & Shuja, S. Paraneoplastic necrotizing myopathy presenting as severe muscle weakness in a patient with small-cell lung cancer: successful response to chemoradiation therapy. Clin. Adv. Hematol. Oncol. 9, 557\u2013566 (2011).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"515_CR55","volume":"6","author":"J Lim","year":"2019","unstructured":"Lim, J. et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol. Neuroimmunol. Neuroinflamm. 6, e513 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"515_CR56","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","volume":"72","author":"CD Kassardjian","year":"2015","unstructured":"Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M. & Milone, M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 72, 996\u20131003 (2015).","journal-title":"JAMA Neurol."},{"key":"515_CR57","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","volume":"67","author":"JJ Paik","year":"2015","unstructured":"Paik, J. J. et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res. 67, 1416\u20131425 (2015).","journal-title":"Arthritis Care Res."},{"key":"515_CR58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"Benveniste, O., Stenzel, W. & Allenbach, Y. Advances in serological diagnostics of inflammatory myopathies. Curr. Opin. Neurol. 29, 662\u2013673 (2016).","journal-title":"Curr. Opin. Neurol."},{"key":"515_CR59","doi-asserted-by":"crossref","first-page":"102465","DOI":"10.1016\/j.autrev.2020.102465","volume":"19","author":"N Wesner","year":"2020","unstructured":"Wesner, N. et al. Anti-RNP antibodies delineate a subgroup of myositis: a systematic retrospective study on 46 patients. Autoimmun. Rev. 19, 102465 (2020).","journal-title":"Autoimmun. Rev."},{"key":"515_CR60","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","volume":"92","author":"M Casal-Dominguez","year":"2019","unstructured":"Casal-Dominguez, M. et al. Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology 92, e1416\u2013e1426 (2019).","journal-title":"Neurology"},{"key":"515_CR61","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000523","volume":"6","author":"P Mohassel","year":"2019","unstructured":"Mohassel, P. et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol. Neuroimmunol. Neuroinflamm. 6, e523 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"515_CR62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao, A. H., Lacomis, D., Lucas, M., Fertig, N. & Oddis, C. V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50, 209\u2013215 (2004).","journal-title":"Arthritis Rheum."},{"key":"515_CR63","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2169\/internalmedicine.2564-18","volume":"58","author":"S Takeguchi-Kikuchi","year":"2019","unstructured":"Takeguchi-Kikuchi, S. et al. Anti-signal recognition particle antibody-positive necrotizing myopathy with secondary cardiomyopathy: the first myocardial biopsy- and multimodal imaging-proven case. Intern. Med. 58, 3189\u20133194 (2019).","journal-title":"Intern. Med."},{"key":"515_CR64","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1161\/CIRCULATIONAHA.112.118877","volume":"127","author":"M Thi\u00e9baut","year":"2013","unstructured":"Thi\u00e9baut, M. et al. Antisignal recognition particle antibodies-related cardiomyopathy. Circulation 127, e434\u2013e436 (2013).","journal-title":"Circulation"},{"key":"515_CR65","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230213","volume":"12","author":"M Pitlick","year":"2019","unstructured":"Pitlick, M. & Ernste, F. Anti-HMGCR myopathy presenting with acute systolic heart failure. BMJ Case Rep. 12, e230213 (2019).","journal-title":"BMJ Case Rep."},{"key":"515_CR66","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","volume":"5","author":"M Rigolet","year":"2019","unstructured":"Rigolet, M. et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open 5, e000811 (2019).","journal-title":"RMD Open"},{"key":"515_CR67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nan.12519","volume":"45","author":"A Uruha","year":"2019","unstructured":"Uruha, A. et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol. Appl. Neurobiol. 45, 513\u2013522 (2019).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"515_CR68","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000558","volume":"6","author":"S Knauss","year":"2019","unstructured":"Knauss, S. et al. PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited. Neurol. Neuroimmunol. Neuroinflamm. 6, e558 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"515_CR69","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","volume":"181","author":"C Preu\u00dfe","year":"2012","unstructured":"Preu\u00dfe, C. et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am. J. Pathol. 181, 2161\u20132171 (2012).","journal-title":"Am. J. Pathol."},{"key":"515_CR70","first-page":"3069","volume":"8","author":"X Yin","year":"2015","unstructured":"Yin, X. et al. CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy. Int. J. Clin. Exp. Pathol. 8, 3069\u20133075 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"515_CR71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","volume":"30","author":"N Fischer","year":"2019","unstructured":"Fischer, N. et al. Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies. Brain Pathol. 30, 261\u2013271 (2019).","journal-title":"Brain Pathol."},{"key":"515_CR72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.26608","volume":"60","author":"F Girolamo","year":"2019","unstructured":"Girolamo, F. et al. Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. Muscle Nerve 60, 315\u2013327 (2019).","journal-title":"Muscle Nerve"},{"key":"515_CR73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nmd.2012.09.001","volume":"23","author":"NWJ Schr\u00f6der","year":"2013","unstructured":"Schr\u00f6der, N. W. J. et al. Pipestem capillaries in necrotizing myopathy revisited. Neuromuscul. Disord. 23, 66\u201374 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"515_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.02.009","author":"O Landon-Cardinal","year":"2020","unstructured":"Landon-Cardinal, O. et al. Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Semin. Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.009 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"515_CR75","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1210\/en.2012-1573","volume":"153","author":"E Pimenta","year":"2012","unstructured":"Pimenta, E., Wolley, M. & Stowasser, M. Adverse cardiovascular outcomes of corticosteroid excess. Endocrinology 153, 5137\u20135142 (2012).","journal-title":"Endocrinology"},{"key":"515_CR76","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.autrev.2011.10.024","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie, I. et al. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun. Rev. 11, 615\u2013620 (2012).","journal-title":"Autoimmun. Rev."},{"key":"515_CR77","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3899\/jrheum.090549","volume":"36","author":"BB Antiochos","year":"2009","unstructured":"Antiochos, B. B. et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J. Rheumatol. 36, 2704\u20132710 (2009).","journal-title":"J. Rheumatol."},{"key":"515_CR78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res. Ther. 19, 259 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"515_CR79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","volume":"81","author":"L Arouche-Delaperche","year":"2017","unstructured":"Arouche-Delaperche, L. et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann. Neurol. 81, 538\u2013548 (2017).","journal-title":"Ann. Neurol."},{"key":"515_CR80","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.40883","volume":"71","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez, I. et al. Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheumatol. 71, 1371\u20131376 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"515_CR81","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1242\/jcs.03371","volume":"120","author":"V Jacquemin","year":"2007","unstructured":"Jacquemin, V., Butler-Browne, G. S., Furling, D. & Mouly, V. IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes. J. Cell Sci. 120, 670\u2013681 (2007).","journal-title":"J. Cell Sci."},{"key":"515_CR82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0092-8674(03)00319-2","volume":"113","author":"V Horsley","year":"2003","unstructured":"Horsley, V., Jansen, K. M., Mills, S. T. & Pavlath, G. K. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113, 483\u2013494 (2003).","journal-title":"Cell"},{"key":"515_CR83","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jcb.24077","volume":"113","author":"L Trapani","year":"2012","unstructured":"Trapani, L. et al. 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration. J. Cell. Biochem. 113, 2057\u20132063 (2012).","journal-title":"J. Cell. Biochem."},{"key":"515_CR84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua, C. et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann. Rheum. Dis. 78, 131\u2013139 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR85","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","volume":"11","author":"K Albazli","year":"2020","unstructured":"Albazli, K., Kaminski, H. J. & Howard, J. F. Complement inhibitor therapy for Myasthenia Gravis. Front. Immunol. 11, 917 (2020).","journal-title":"Front. Immunol."},{"key":"515_CR86","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04025632 (2020)."},{"key":"515_CR87","unstructured":"PubChem. Zilucoplan. PubChem https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/133083018 (2018)."},{"key":"515_CR88","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","volume":"22","author":"A Meyer","year":"2020","unstructured":"Meyer, A. et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res. Ther. 22, 5 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"515_CR89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito, P. et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41, 185\u2013190 (2010).","journal-title":"Muscle Nerve"},{"key":"515_CR90","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000096","volume":"2","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan, S. et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol. Neuroimmunol. Neuroinflamm. 2, e96 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"515_CR91","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil, R., Casciola-Rosen, L., Hong, G., Mammen, A. & Christopher-Stine, L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 62, 1328\u20131334 (2010).","journal-title":"Arthritis Care Res."},{"key":"515_CR92","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","volume":"46","author":"O Landon-Cardinal","year":"2019","unstructured":"Landon-Cardinal, O. et al. Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy. J. Rheumatol. 46, 623\u2013627 (2019).","journal-title":"J. Rheumatol."},{"key":"515_CR93","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","volume":"44","author":"SL Tansley","year":"2017","unstructured":"Tansley, S. L. et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J. Rheumatol. 44, 488\u2013492 (2017).","journal-title":"J. Rheumatol."},{"key":"515_CR94","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns, E. L. et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatr. Rheumatol. 15, 77 (2017).","journal-title":"Pediatr. Rheumatol."},{"key":"515_CR95","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2169\/internalmedicine.0303-17","volume":"57","author":"T Kusumoto","year":"2018","unstructured":"Kusumoto, T. et al. Development of necrotizing myopathy following interstitial lung disease with anti-signal recognition particle antibody. Intern. Med. 57, 2045\u20132049 (2018).","journal-title":"Intern. Med."},{"key":"515_CR96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03009742.2015.1132761","volume":"45","author":"MG Giudizi","year":"2016","unstructured":"Giudizi, M. G. et al. Anti-HMGCR antibody-associated necrotizing myopathy: diagnosis and treatment illustrated using a case report. Scand. J. Rheumatol. 45, 427\u2013429 (2016).","journal-title":"Scand. J. Rheumatol."},{"key":"515_CR97","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen, A. L. & Tiniakou, E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N. Engl. J. Med. 373, 1680\u20131682 (2015).","journal-title":"N. Engl. J. Med."},{"key":"515_CR98","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","volume":"71","author":"E Tiniakou","year":"2019","unstructured":"Tiniakou, E., Rivera, E., Mammen, A. L. & Christopher-Stine, L. Use of proprotein convertase Subtilisin\/Kexin Type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol. 71, 1723\u20131726 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"515_CR99","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11926-014-0429-4","volume":"16","author":"L Alemo Munters","year":"2014","unstructured":"Alemo Munters, L., Alexanderson, H., Crofford, L. J. & Lundberg, I. E. New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr. Rheumatol. Rep. 16, 429 (2014).","journal-title":"Curr. Rheumatol. Rep."},{"key":"515_CR100","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s10067-019-04571-9","volume":"38","author":"A Van Thillo","year":"2019","unstructured":"Van Thillo, A., Vulsteke, J.-B., Van Assche, D., Verschueren, P. & De Langhe, E. Physical therapy in adult inflammatory myopathy patients: a systematic review. Clin. Rheumatol. 38, 2039\u20132051 (2019).","journal-title":"Clin. Rheumatol."},{"key":"515_CR101","unstructured":"Surmachevska, N. & Tiwari, V. Corticosteroid Induced Myopathy (StatPearls Publishing, 2020)."},{"key":"515_CR102","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139","author":"M Kostine","year":"2020","unstructured":"Kostine, M. et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"515_CR103","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","volume":"76","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez, I. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 76, 681\u2013687 (2017).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00515-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00515-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00515-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T19:32:48Z","timestamp":1634844768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00515-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-00515-9","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"17 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}